Symposium on the High-Quality Development of Mongolian Medicine
On October 16th, the Symposium on the High-Quality Development of Mongolian Medicine and the release conference of 'White Paper on the Chinese Mongolian Medicine Market' were held in Beijing. The main guests attending this meeting included Liu Ping, Secretary-General of the Chinese Society of Ethnomedicine, Ulan, Standing Committee Member of the Inner Mongolia Autonomous Region Political Consultative Conference, O· Uliji, President of the Inner Mongolia Mongolian Medicine Engineering Technology Research Institute, Dong Jingcheng, President of the Fudan University Institute of Integrated Traditional Chinese and Western Medicine, and Zhou Mingzi, Executive Director of Frost & Sullivan Greater China, and Xiang Gongwei, Chairman of Otorqi Mongolian Medicine.
At this symposium, Frost & Sullivan (Frost & Sullivan, abbreviated as 'Frost & Sullivan') officially released the 'White Paper on the Chinese Mongolian Medicine Market' (hereinafter referred to as 'the White Paper').The White Paper points out that in recent years, as the influence of ethnic medicine in the global healthcare system has gradually increased, the industry is facing dual challenges of integrating modernization with traditional theories. In the development of the ethnic medicine industry, there are still gaps between ethnic medicine and modern medicine in terms of theoretical systems and clinical applications, especially in standardization and internationalization, which require further efforts. Therefore, promoting the deep integration of ethnic medicine with modern medicine is not only the key to enhancing the international competitiveness of ethnic medicine but also an inevitable trend for future development.
Mongolian medicine, as a treasure in the treasure house of Chinese ethnic medicine, not only carries profound ethnic culture but also forms an independent and complete medical and pharmaceutical system. Together with traditional Chinese medicine, Tibetan medicine, and Uyghur medicine, it constructs China's 'one belt, three zones' medical pattern, closely united like pomegranate seeds, jointly maintaining the health of the people. The White Paper details the origin, classification, and unique pharmacological value of Mongolian medicine. Mongolian medicine occupies an important position in the domestic pharmaceutical market due to its unique cultural background and clinical application value. However, with the continuous evolution of the modern healthcare system, Mongolian medicine faces challenges in standardized production and sustainable management of medicinal material resources. Although the market penetration rate of Mongolian medicine has gradually increased in recent years, there is still much room for improvement in quality standardization and clinical normalization.
Facing many pain points in the modernization process of Mongolian medicine, the White Paper proposes a series of practical solutions. The current main problems in the Mongolian medicine industry include outdated market concepts, an urgent need to accelerate the modernization process, insufficient evidence-based support for Mongolian medicine theory in modern medicine, and low acceptance of Mongolian medicine by doctors and patients. At the same time, the approval process for Mongolian medicine is not perfect, and approval of articles is slow, requiring policy attention. The White Paper suggests introducing modern technological means to improve the quality control and standardization level of Mongolian medicine production, while increasing the clinical application and promotion of Mongolian medicine, and gradually promoting the modernization standard construction of Mongolian medicine theory. These strategies will help Mongolian medicine overcome current industry pain points and pave the way for its sustainable development in the future.
Looking ahead, the market pattern of the Chinese Mongolian medicine industry will continue to move towards internationalization and modernization. The White Paper points out that with the advancement of the 'Belt and Road' initiative, the influence of the Mongolian medicine industry in the global market is expected to further expand. The Mongolian medicine industry will enhance its international recognition through cultural dissemination and promote its layout and application in the global market. This will become an important strategic path for future industry development. At the same time, improving the industrial chain, strengthening brand building, and enhancing core competitiveness are all key factors for Mongolian medicine enterprises to remain invincible in global competition.
Xiang Gongwei, Chairman of Otorqi Mongolian Medicine, proposed at the symposium that Mongolian patent medicine production enterprises must take on the main responsibility for the industrial development of Mongolian patent medicine. Enterprises should focus on market-oriented development strategies and regard marketization as the core competitiveness of Mongolian patent medicine enterprises. In addition, focusing on the product itself, through access arrangements in medical insurance and essential drug catalogs, promote Mongolian medicine to leave Inner Mongolia and ultimately enter the mainstream national pharmaceutical market. At the same time, innovative research and development is the key to the high-quality development of Mongolian patent medicine. Enterprises should follow the development path of integrating traditional Chinese and Western medicine, industry-university-research cooperation, and actively promote the post-market comprehensive evaluation of core major varieties of Mongolian patent medicine, strengthen the innovative research and development of Mongolian patent medicine and the standardization of Mongolian medicine theory, so as to better serve the life and health of the general public.
The participants at the symposium unanimously agreed that the high-quality development of Mongolian medicine requires efforts in multiple aspects. These include policy incentives and regulatory intervention, technological upgrading and capability innovation, the commercialization transformation ability of technology, industrial chain ecosystem construction, stable raw material sources, and other important aspects.
The convening of the Symposium on the High-Quality Development of Mongolian Medicine provides an important platform for the inheritance and innovation of Mongolian medicine. The 'White Paper on the Chinese Mongolian Medicine Market' will also continue to play its guiding and instructive role, providing new impetus for the development of Mongolian medicine.
